130 related articles for article (PubMed ID: 11493755)
1. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors.
Furuya M; Ishikura H; Ogawa Y; Kawarada Y; Shibata M; Fujimoto S; Yoshiki T
Pathobiology; 2000; 68(6):239-44. PubMed ID: 11493755
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
4. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography.
Furuya M; Ishikura H; Nemori R; Shibata M; Fujimoto S; Yoshiki T
Hum Pathol; 2001 Feb; 32(2):163-8. PubMed ID: 11230703
[TBL] [Abstract][Full Text] [Related]
5. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
6. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP.
Becher N; Hein M; Uldbjerg N; Danielsen CC
Reprod Biol Endocrinol; 2008 Sep; 6():45. PubMed ID: 18826601
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
8. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors.
Furuya M
Hokkaido Igaku Zasshi; 1999 Mar; 74(2):145-55. PubMed ID: 10386163
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Murthi P; Barker G; Nowell CJ; Rice GE; Baker MS; Kalionis B; Quinn MA
Gynecol Oncol; 2004 Jan; 92(1):80-8. PubMed ID: 14751142
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma.
Ripley D; Tunuguntla R; Susi L; Chegini N
Int J Gynecol Cancer; 2006; 16(5):1794-800. PubMed ID: 17009974
[TBL] [Abstract][Full Text] [Related]
12. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and their inhibitors in human pituitary tumors.
Beaulieu E; Kachra Z; Mousseau N; Delbecchi L; Hardy J; Béliveau R
Neurosurgery; 1999 Dec; 45(6):1432-40; discussion 1440-1. PubMed ID: 10598711
[TBL] [Abstract][Full Text] [Related]
14. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
15. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
[TBL] [Abstract][Full Text] [Related]
16. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Matrix Metalloproteinases and their Inhibitors in Bovine Cystic Ovarian Disease.
Peralta MB; Baravalle ME; Belotti EM; Stassi AF; Salvetti NR; Ortega HH; Rey F; Velázquez MML
J Comp Pathol; 2017; 156(2-3):191-201. PubMed ID: 27993358
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
19. Is collagen breakdown during periodontitis linked to inflammatory cells and expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gingival tissue?
Séguier S; Gogly B; Bodineau A; Godeau G; Brousse N
J Periodontol; 2001 Oct; 72(10):1398-406. PubMed ID: 11699482
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas.
Tomita T; Iwata K
Dis Colon Rectum; 1996 Nov; 39(11):1255-64. PubMed ID: 8918435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
